DCOY Salarius Pharmaceuticals, Inc. Insider Trading

Director Hanish Arnold C buys 5,000 shares of SLRX at $0.75; stock down 98.3% from $55.05 52-week high, revenue $0.00, net loss $-873.5K.

Director Hanish Arnold C purchased 5,000 shares at $0.75, expanding his holdings from 15 shares to 5,015 shares—a net increase of 5,000 shares. The purchase occurs in the context of severe financial and operational deterioration: the company reported zero revenue in its latest quarter, a full-year net loss of $-873,467.00, annual revenue decline of -100.0%, and a 52-week price decline of 98.3% from the $55.05 high. The stock trades at $0.95 currently, down 75.9% over 30 days and 83.5% over 90 days. The company's $5.6M market cap and unprofitable status compound the risk profile. This purchase by a director at depressed price levels during a period of operational distress and dramatic stock deterioration warrants investor scrutiny regarding the company's viability and management's confidence.

CFO Mark J Rosenblum bought 20,000 shares at $0.80 on 2025-11-20 amid -80.2% 30-day price collapse and -$873.5K quarterly net loss.

Mark J Rosenblum, Exec VP Finance and CFO of Salarius Pharmaceuticals, purchased 20,000 shares at $0.80 on 2025-11-20, increasing his holdings from 177 shares to 20,177 shares. The transaction occurred in an extreme distress environment: the stock has declined -80.2% over the past 30 days and -87.0% over 90 days, currently trading at $0.75 versus a 52-week high of $55.05 (a -98.6% decline). The company reported zero revenue in its latest quarter and a net loss of -$873.5K, with annual revenue down -100.0% year-over-year; the market cap stands at only $4.4M. This insider purchase of a meaningful position by a senior financial executive during a period of extreme price deterioration and documented operational distress suggests a notable commitment at deeply depressed levels, though the lack of profitability and revenue contraction raise structural questions about company viability.